Platelet activation and vascular endothelial growth factor 165 release in hepatocellular cancer

Clinica Chimica Acta

Volumn 412, Issue 5-6, 2011, Pages 450-454

  Ferroni, Patrizia ^a   Spila, Antonella ^a   D'Alessandro, Roberta ^a   Martini, Francesca ^a   Iacovone, Francesca ^a   Ettorre, Giuseppe M ^b   Vennarecci, Giovanni ^b   Santoro, Roberto ^b   Puoti, Claudio ^c   Guadagni, Fiorella ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c Marino Hospital Rome   (Italy)

Author keywords

Angiogenesis; Hepatocellular carcinoma; Platelet activation; Vascular endothelial growth factor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PADGEM PROTEIN; VASCULOTROPIN 165;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN SECRETION; PROTHROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPLASTIN TIME; TUMOR VOLUME;

BLOOD CHEMICAL ANALYSIS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-SELECTIN; PLATELET ACTIVATION; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650907073     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.11.026     Document Type: Article

References (25)

1. Yu A.S., Keeffe E.B. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003, 3:8-24.
2. El-Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
3. Joist H.J. Hemostatic abnormalities in liver disease. Hemostasis and thrombosis. Basic principle and clinical practice 1994, 906-920. JB Lippincott Company, Philadelphia. 3rd ed. R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.).
4. Rubin M.H., Weston M.J., Langley P.G., White Y., Williams R. Platelet function in chronic liver disease: relationship to disease severity. Dig Dis Sci 1979, 24:197-202.
5. Davi G., Ferro D., Basili S., et al. Increased thromboxane metabolites excretion in liver cirrhosis. Thromb Haemost 1998, 79:747-751.
6. Ferroni P., Mammarella A., Martini F., et al. Increased soluble P-selectin levels in HCV-related chronic hepatitis. Correlation with viral load. J Invest Med 2001, 49:407-412.
7. Vardareli E., Saricam T., Demirustu C., Gulbas Z. Soluble P-selectin levels in chronic liver disease: relationship to disease severity. Hepatogastroenterol 2007, 54:466-469.
8. Morsi M.I., Hussein A.E., Mostafa M., El-Abd E., El-Moneim N.A. Evaluation of tumour necrosis factor-α, soluble P-selectin, γ-glutamyl transferase, glutathione S-transferase-π and α-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci 2006, 63:74-78.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Banks R.E., Forbes M.A., Kinsey S.E., et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998, 77:956-964.
11. Poon R.T., Ng I.O., Lau C., et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002, 20:1775-1785.
12. Kaseb A.O., Hanbali A., Cotant M., Hassan M.M., Wollner I., Philip P.A. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009, 115:4895-4906.
13. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100:1385-1392.
14. Tamesa T., Iizuka N., Mori N., et al. High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterol 2009, 56:1122-1126.
15. Gadelhak N.A., Gadelhak S.A., El-Morsi D.A., Abdelaziz M.M., Abbas A.T., El-Emshaty H.M. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Hepatogastroenterol 2009, 56:1417-1424.
16. Mohle R., Green D., Moore M.A., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997, 94:663-668.
17. Verheul H.M., Hoekman K., Luykx-de Bakker S., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3:2187-2190.
18. George M.L., Eccles S.A., Tutton M.G., Abulafi A.M., Swift R.I. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res 2000, 6:3147-3152.
19. Roselli M., Mineo T.C., Martini F., et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer. Relationship with coagulation and platelet activation markers. Thromb Haemost 2003, 89:177-184.
20. Fijnheer R., Frijns C.J.M., Korteweg J., et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997, 77:1081-1085.
21. Poon T.P., Lau P.Y., Cheung S.T., Yu W.C., Fan S.T. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003, 63:3121-3126.
22. Kim S.J., Choi I.K., Park K.H., et al. Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol 2004, 34:184-190.
23. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001, 47:617-623.
24. Dittadi R., Meo S., Fabris F., et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001, 16:87-96.
25. Finn R.S., Zhu A.X. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009, 9:503-509.